Status:

COMPLETED

Comparison of Immunosuppression Protocols After LTx in Children

Lead Sponsor:

Children's Memorial Health Institute, Poland

Conditions:

Liver Transplantation

Eligibility:

All Genders

Up to 18 years

Phase:

PHASE4

Brief Summary

Open label, randomised, prospective, onecentre Investigator Driven Study: Comparison of two protocols of immunosuppression after liver Tx in children: A: Study group - FK506-MMF. Immunosupression pr...

Detailed Description

A: Study group FK506-MMF. Immunosupression protocol: Metylprednisolon 10 mg/kg intraoperatively i.v. FK506 Day 0 or 1 oraly (0,15 mg/kg/D in two doses). MMF max. dosage 30 mg/kg/D p.o. day 0 thro...

Eligibility Criteria

Inclusion

  • Subjects who meet all of the following criteria are eligible for this study:
  • Male or female patients, not older than 18 years old.
  • Primary liver transplantation
  • Patient is capable of understanding the purpose and risks of the study and has been informed both orally and in writing and has given informed consent

Exclusion

  • Subjects who meet one or more of the following criteria are not eligible for this study:
  • Female patients who are pregnant or are breast feeding
  • Patients \> 18 years old
  • Combined liver-kidney transplantation
  • Recipient of second liver graft
  • Patients are allergic, hyper-sensitive or intolerant to HCO-60 or structurally related compounds, macrolide antibiotics or tacrolimus.
  • Patients with known HIV-anamnesis
  • Patient requires ongoing dosing with a systemic immunosuppressive drug at study entry for another indication than the prophylaxis of liver graft rejection
  • Patient has significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, or active peptic ulcer.
  • Patient is participating or has participated in another clinical study and/or is taking or has been taking an investigational drug in the past 28 days.
  • Other reasons which depend on the assessment of the physician (no MMF will be given to patients with severe persistent hypersplenism (WBC \< 3.500/ml, platelets \< 50.000/ml)

Key Trial Info

Start Date :

September 1 2002

Trial Type :

INTERVENTIONAL

End Date :

July 1 2006

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00195988

Start Date

September 1 2002

End Date

July 1 2006

Last Update

November 17 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Pediatric Surgery and Organ Transplantation, CMHI

Warsaw, Poland, 04-743